Early Report on Published Outcomes in Kidney Transplant Recipients Compared to Nontransplant Patients Infected With Coronavirus Disease 2019.
Acute Kidney Injury
/ epidemiology
Betacoronavirus
COVID-19
Coronavirus Infections
/ complications
Female
Humans
Immunocompromised Host
Incidence
Kidney Transplantation
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ complications
Renal Replacement Therapy
/ statistics & numerical data
SARS-CoV-2
Young Adult
Journal
Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
14
06
2020
revised:
18
06
2020
accepted:
08
07
2020
pubmed:
6
8
2020
medline:
6
11
2020
entrez:
6
8
2020
Statut:
ppublish
Résumé
Kidney transplant recipients (KTR) present unique characteristics, including disease vintage, immunosuppression, and single functioning kidneys. We conducted preliminary analyses to assess the impact of coronavirus disease 2019 (COVID-19) on outcomes in KTR compared to nontransplant patients. We evaluated published information in peer-reviewed journals between January 1, 2020, and April 24, 2020, with available data on acute kidney injury (AKI), renal replacement therapy (RRT), intensive care unit (ICU) stay, and death and compared clinical outcomes in KTR vs nontransplant recipients with COVID-19. A total of 19 published articles were identified, including a total of 88 KTR and 5342 nontransplant patients. The sample size varied between 2 and 2634. Mean age was 58.6 years vs 58.9 years in KTR vs nontransplant patients. Patient-level incidence of AKI (27.5% vs 13.3%, P < .001), RRT (15.4% vs 3.3%, P < .001), ICU stay (34.1% vs 15.1%, P < .001), and death (22.7% vs 16.2%, P = .10) was higher in KTR, representing relative risks of 2.06 (1.44, 2.96), 4.72 (2.62, 8.51), 2.25 (1.67, 3.03), and 1.41 (0.95, 2.08), respectively. Early results suggest that the KTR are at significantly higher risk of AKI, RRT, and ICU stay from SARS-CoV-19 infection compared to the general population. The risk of death may not be significantly different.
Sections du résumé
BACKGROUND
BACKGROUND
Kidney transplant recipients (KTR) present unique characteristics, including disease vintage, immunosuppression, and single functioning kidneys. We conducted preliminary analyses to assess the impact of coronavirus disease 2019 (COVID-19) on outcomes in KTR compared to nontransplant patients.
METHODS
METHODS
We evaluated published information in peer-reviewed journals between January 1, 2020, and April 24, 2020, with available data on acute kidney injury (AKI), renal replacement therapy (RRT), intensive care unit (ICU) stay, and death and compared clinical outcomes in KTR vs nontransplant recipients with COVID-19.
RESULTS
RESULTS
A total of 19 published articles were identified, including a total of 88 KTR and 5342 nontransplant patients. The sample size varied between 2 and 2634. Mean age was 58.6 years vs 58.9 years in KTR vs nontransplant patients. Patient-level incidence of AKI (27.5% vs 13.3%, P < .001), RRT (15.4% vs 3.3%, P < .001), ICU stay (34.1% vs 15.1%, P < .001), and death (22.7% vs 16.2%, P = .10) was higher in KTR, representing relative risks of 2.06 (1.44, 2.96), 4.72 (2.62, 8.51), 2.25 (1.67, 3.03), and 1.41 (0.95, 2.08), respectively.
CONCLUSION
CONCLUSIONS
Early results suggest that the KTR are at significantly higher risk of AKI, RRT, and ICU stay from SARS-CoV-19 infection compared to the general population. The risk of death may not be significantly different.
Identifiants
pubmed: 32753243
pii: S0041-1345(20)32626-9
doi: 10.1016/j.transproceed.2020.07.002
pmc: PMC7357494
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2659-2662Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Am J Nephrol. 2020;51(5):343-348
pubmed: 32229732
Am J Transplant. 2020 Jul;20(7):1849-1858
pubmed: 32301155
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
N Engl J Med. 2020 Jun 18;382(25):2475-2477
pubmed: 32329975
J Am Soc Nephrol. 2020 Jun;31(6):1150-1156
pubmed: 32317402
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Kidney Int. 2020 Jun;97(6):1083-1088
pubmed: 32354634
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Am J Transplant. 2020 Jul;20(7):1941-1943
pubmed: 32233067
Kidney Int. 2020 Jun;97(6):1076-1082
pubmed: 32354637
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Kidney Int. 2020 Jul;98(1):219-227
pubmed: 32327202
Lancet Respir Med. 2020 Mar;8(3):267-276
pubmed: 32043986